Julie Roda

Julie Roda is an accomplished Director and Head of Translational Science at NGM Biopharmaceuticals, with a focus on developing pharmacodynamic and predictive biomarker assays for immune-oncology clinical trials. With a career spanning over 15 years, Julie has advanced molecules such as NGM831 and NGM936 from target validation through candidate designation, collaborating with diverse scientific teams and establishing unique experimental models. Prior experience includes senior roles at OncoMed Pharmaceuticals, where significant contributions were made to validating receptor-ligand interactions and identifying immuno-oncology therapeutic targets, as well as a research background at The Ohio State University, earning a PhD in cancer immunology. Julie Roda's work is recognized for impactful research in tumor immunology, including a notable publication in Cancer Immunology Research.